Synthetic peptides sit at the centre of antibody work in three distinct roles: as the antigen used to raise an antibody, as the tool used to find out what an antibody recognizes, and as the control used to prove that a signal is specific. The chemistry is the same in all three, but the design requirements are different, and confusing them is a common source of trouble.
A peptide conjugated to a carrier protein raises antibodies against a chosen region, which is useful when the target protein is hard to express, when you need region-specific antibodies, or when you need an antibody against a modified residue. The immune system never sees the folded protein, so the resulting antibodies recognize the linear sequence.
Overlapping, truncated or substituted peptide sets localize what an antibody recognizes, down to individual residues. This matters for patent work, for understanding cross-reactivity, and for knowing whether an antibody will survive a change in sample preparation.
A blocking peptide that abolishes signal, and a mutant or unmodified peptide that does not, is among the most convincing specificity evidence available. Journals and antibody validation initiatives increasingly expect this kind of data.
This is the single most frequent disappointment in peptide antibody projects, and it is predictable rather than bad luck. An antibody raised against a short peptide recognizes that sequence as a linear stretch. Whether it also recognizes the intact protein depends on whether the sequence is exposed and accessible in the folded structure, and on how the protein is presented in the assay.
In a Western blot the protein is denatured, the sequence is laid bare, and a peptide antibody usually performs well. In immunoprecipitation, flow cytometry or immunofluorescence of native protein, the same region may be buried in the fold, hidden by a binding partner, or masked by a post-translational modification. The antibody is not defective; it is being asked to do something it was never selected for.
The practical consequence is that the intended application should drive the antigen choice. If the antibody must recognize native protein, favour regions that are predicted to be surface-exposed and flexible, such as loops and termini, and consider whether a recombinant protein antigen would serve better. Our antigen design page and design analyzer cover how to make that choice.
| Experiment | What it shows |
|---|---|
| ELISA titer against the immunizing peptide | That an immune response was raised, and how strong it is. It does not show that the antibody recognizes the parent protein. |
| Peptide blocking of a Western or IHC signal | That the signal depends on the epitope. Strong evidence for specificity when paired with a non-blocking control peptide. |
| Overlapping peptide scan | Where in the sequence the epitope lies, and whether there is more than one. |
| Alanine or truncation scan | Which individual residues the antibody depends on. |
| Matched modified and unmodified peptides | Whether recognition genuinely requires the modification. |
Carrier antibodies are real
A serum raised against a peptide-KLH conjugate contains antibodies against the carrier as well as the peptide. If an ELISA uses the same carrier for coating, much of the signal may be anti-carrier. Coat with the free peptide, or with the peptide on a different carrier such as BSA, and use affinity-purified antibody for critical work. See carrier protein conjugation.
Paste a peptide or protein sequence to review length, charge, hydrophobicity and other properties before you order.
Research use only. LifeTein peptides and proteins are supplied for laboratory research use. They are not for human or veterinary use, and not for diagnostic or therapeutic use. See our research use policy.
Tell us the protein, the region of interest and the applications the antibody must work in, and we will propose an antigen design and the control peptides to make alongside it. Email sales@lifetein.com or use our antibody service quotation form.